Search Results

While many describe California as having a tough life sciences market, there’s some optimism that employment opportunities will improve soon, according to California Life Sciences President and CEO Mike Guerra.

For the first eight months of 2024, California had the most job postings live on BioSpace—37.7% more than Massachusetts. Last year, Massachusetts ranked No.1 for the same time period.

Biocom California, the association representing the California life science industry, released a new report showing California’s life science industry directly provides more than 465,000 jobs in the state and generates $414.2 billion in total business output.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.

Riverside University Health System is proud to announce the implementation of FloPatch by Flosonics Medical. As a pioneer in adopting new, ground-breaking medical technology, Riverside is making a significant leap forward in healthcare innovation, particularly in the life-saving area of sepsis management.

The Regents of the University of California, on behalf of the University of California, Irvine, has entered into a definitive agreement with Tenet Healthcare Corporation to acquire Tenet’s Pacific Coast Network.

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

ImmunityBio will lay off 16 employees in California and said it expects to need more funding to commercialize Anktiva, approved in April for non-muscle invasive bladder cancer.

Lineage Cell Therapeutics, Inc. today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM).

Amneal Pharmaceuticals, Inc. announced that it has begun supplying its over-the-counter Naloxone Hydrochloride Nasal Spray, USP, 4mg to U.S. retail pharmacies and the State of California.